Abstract
Results of a placebo-controlled double blind randomised trial to investigate the efficacy of rifaximin-alpha versus placebo in improving systemic inflammation in patients with cirrhosis and chronic hepatic encephalopathy (RIFSYS Trial)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have